Reversal of the antichlamydial activity of putative type III secretion inhibitors by iron. - sprookjes - yvandenbroek - TriplyDB

Reversal of the antichlamydial activity of putative type III secretion inhibitors by iron.

Reversal of the antichlamydial activity of putative type III secretion inhibitors by iron.

http://www.wikidata.org/entity/Q37859892

about

Chemical inhibitors of the type three secretion system: disarming bacterial pathogens From screen to target: insights and approaches for the development of anti-virulence compounds Space: A Final Frontier for Vacuolar Pathogens Isolation of Salmonella mutants resistant to the inhibitory effect of Salicylidene acylhydrazides on flagella-mediated motility Formulation of the microbicide INP0341 for in vivo protection against a vaginal challenge by Chlamydia trachomatis Mutations in hemG mediate resistance to salicylidene acylhydrazides, demonstrating a novel link between protoporphyrinogen oxidase (HemG) and Chlamydia trachomatis infectivity.Small-molecule type III secretion system inhibitors block assembly of the Shigella type III secreton.Exploration of chlamydial type III secretion system reconstitution in Escherichia coli.Small molecule inhibitors of the Yersinia type III secretion system impair the development of Chlamydia after entry into host cells Haptoglobin and sickle cell polymorphisms and risk of active trachoma in Gambian children.The Chlamydia trachomatis type III secretion substrates CT142, CT143, and CT144 are secreted into the lumen of the inclusion.Candidate vaginal microbicides with activity against Chlamydia trachomatis and Neisseriagonorrhoeae.Benzylidene acylhydrazides inhibit chlamydial growth in a type III secretion- and iron chelation-independent manner.The type III secretion system (T3SS) of Chlamydophila psittaci is involved in the host inflammatory response by activating the JNK/ERK signaling pathway Chlamydia trachomatis secretion of hypothetical protein CT622 into host cell cytoplasm via a secretion pathway that can be inhibited by the type III secretion system inhibitor compound 1.Protection of mice from a Chlamydia trachomatis vaginal infection using a Salicylidene acylhydrazide, a potential microbicide.Application of β-lactamase reporter fusions as an indicator of effector protein secretion during infections with the obligate intracellular pathogen Chlamydia trachomatis Type III Secretion-Dependent Sensitivity of Escherichia coli O157 to Specific Ketolides Andrographolide inhibits intracellular Chlamydia trachomatis multiplication and reduces secretion of proinflammatory mediators produced by human epithelial cells.Pre-clinical pharmacokinetics and anti-chlamydial activity of salicylidene acylhydrazide inhibitors of bacterial type III secretion In vitro anti-HIV-1 activity of salicylidene acylhydrazide compounds Role for the chlamydial type III secretion apparatus in host cytokine expression.Inflammasome-dependent caspase-1 activation in cervical epithelial cells stimulates growth of the intracellular pathogen Chlamydia trachomatis.Chlamydial biology and its associated virulence blockers.Analysis of Chlamydia pneumoniae infection in mononuclear cells by reverse transcription-PCR targeted to chlamydial gene transcripts.Promoters for Chlamydia type III secretion genes show a differential response to DNA supercoiling that correlates with temporal expression pattern.Virulence blockers as alternatives to antibiotics: type III secretion inhibitors against Gram-negative bacteria.Targeting the type III secretion system to treat bacterial infections.Development of antivirulence compounds: a biochemical review.Approaches targeting the type III secretion system to treat or prevent bacterial infections.Identification of bacterial target proteins for the salicylidene acylhydrazide class of virulence-blocking compounds.Anti-virulence Strategies to Target Bacterial Infections.Cytosporone B, an inhibitor of the type III secretion system of Salmonella enterica serovar Typhimurium.The salicylidene acylhydrazide INP0341 attenuates Pseudomonas aeruginosa virulence in vitro and in vivo.Salicylidene Acylhydrazides and Hydroxyquinolines Act as Inhibitors of Type Three Secretion Systems in Pseudomonas aeruginosa by Distinct Mechanisms.Pseudoceramines A-D, new antibacterial bromotyrosine alkaloids from the marine sponge Pseudoceratina sp.Small molecules aimed at type III secretion systems to inhibit bacterial virulence The bacterial type III secretion system as a target for developing new antibiotics Identification of a strong and specific antichlamydial N-acylhydrazone.Characterization of the effects of salicylidene acylhydrazide compounds on type III secretion in Escherichia coli O157:H7.

P2860

Q27013353-6D75BFE2-C5FE-4E39-B6A0-7DF34B5E758F Q27026390-0D34AB67-F58A-411C-AEB7-9C3BEB553212 Q28078953-823B232A-F526-48EA-8823-0662F2455604 Q28484814-0C96A1FD-D089-4591-8A3D-46E1F0086691 Q28544625-3522C965-6F0C-4455-81F4-B4759D8FED7E Q30449313-1BA3E368-60E0-4910-ABA6-C299E49F4E75 Q30853039-9E1B8039-3099-4577-B732-17F873FB5634 Q31109123-7876C242-4CAA-49A9-AC21-66AA5BF684C4 Q33433231-949DA648-1510-43AC-8DF2-7DC4016D0C63 Q33605747-54A56E39-7DD7-4D26-8848-DC9DE18901A4 Q33806902-822524C3-9A49-402B-B464-D60D1D5F9228 Q33987702-AF134D3B-32C5-42C3-AE71-5364FA61ED01 Q34056674-D182BBDA-A462-4983-AD7F-82619324CFE1 Q35050716-14CDBDE0-A1BC-45B9-9283-8396800C5404 Q35114743-7FBC90D3-ECB8-46C9-AB79-740359505C5A Q35238168-9C8CCA64-640C-42BA-9891-5D39C5C142BA Q35741537-9178A0B2-E229-48FE-BFBE-F45EBCAD7975 Q35829561-82151106-E762-4D02-91A3-46C9B3F21D2A Q35975515-4D1CC337-7F0C-42A4-B27A-32F0F0CC894B Q36192395-82369D00-36DD-445C-AF37-DE94523F274D Q36223323-8F9A8236-CD9F-4795-BA50-8594BD59CE4A Q37032989-0145A5B2-87DA-4A45-95CD-925B712FD47D Q37446814-894F94F2-1D11-4DA5-BFE3-B82F399A9A95 Q37847713-0B53B172-3841-49A2-A716-A378BA3A7091 Q37851467-55A72B97-3CFF-4881-A292-14B3E6DE451D Q37853449-BDD3613B-9FA6-4ECF-B34B-895570D9DA34 Q37857710-FB696929-E994-4493-BFC7-F4C546282D06 Q38167861-C9A536C1-FC50-4006-9009-F8000FB890FA Q38293001-5C1E84FE-BE0D-45B2-A6F0-077B894C0E36 Q38366322-2AC378C3-A62E-4CA7-8FC9-B99CA90D688A Q38676435-31EB3376-92AF-41E5-AE2E-F7307DA22DEE Q38760476-503987B6-9676-4DFF-9652-4A239BE00490 Q40004916-245EA87E-08C6-47E2-99F9-EC70DE716EDF Q40182759-36B6336E-FE2B-4024-86E0-617E252EDB56 Q40257063-7272C606-FEB7-4865-84FD-E7A9F902D9FA Q41427000-D0523CFA-80C9-4AA2-A6B3-2E0D47A74C8E Q41974659-2AD75A54-3C64-47D7-94FE-F40E9C389446 Q42328253-E561BBBF-AA9B-4725-9DF6-94760B1BA615 Q42369614-2EC8596F-23A0-48BE-94C0-95458C6582D2 Q42561295-DA099342-2DCC-45BC-8FAC-A82048456DCF

P2860

Reversal of the antichlamydial activity of putative type III secretion inhibitors by iron.

http://www.wikidata.org/entity/Q37859892

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 30 April 2007

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Reversal of the antichlamydial ...... secretion inhibitors by iron.

@en

Reversal of the antichlamydial ...... secretion inhibitors by iron.

@nl

type

label

Reversal of the antichlamydial ...... secretion inhibitors by iron.

@en

Reversal of the antichlamydial ...... secretion inhibitors by iron.

@nl

prefLabel

Reversal of the antichlamydial ...... secretion inhibitors by iron.

@en

Reversal of the antichlamydial ...... secretion inhibitors by iron.

@nl

P1433

Q37859892-6A5418C6-750E-4479-BC87-60C120CDFFE1

P1476

Q37859892-481D780B-7E44-4020-A944-5A58405DD0B6

P2093

Q37859892-051C345C-1686-4755-9ED0-6A9C484BEF24

Q37859892-60D5CF42-193F-4AC1-BB4C-0EFE2553EC4D

Q37859892-826172E6-115F-41BD-A376-E9CF199E37E8

Q37859892-867ED7C3-2BD2-4E22-81EE-5605BEDC9269

Q37859892-88EF66AF-02E7-4C41-B30A-555789F61007

Q37859892-DB92BA77-4A47-4C9B-B739-BD172A98B637

P2860

Q37859892-003C7CE3-B6C9-4897-BF47-AC116CDB292A

Q37859892-03720A15-EA5F-4970-8BC0-8E4903C51651

Q37859892-1A68B8B5-6A07-48A9-ABDE-C890741B594D

Q37859892-1C7B8BE8-2AFC-44FB-B2FB-2C7DD76AECD1

Q37859892-1DE86752-796B-43BA-A6F0-A825564DF131

Q37859892-2925C85B-07D2-40CE-9A7F-2C93104FAF89

Q37859892-2FAB9220-14C0-47DB-837C-2E3E9E5296C9

Q37859892-3084BC56-B5C5-4F1D-9E2E-70FA3CDE831E

Q37859892-44636ACB-8A6F-451C-B466-86B40C6FE5E6

Q37859892-5D5ED5E7-8D9C-4EC2-BEF1-3EA9C1E3C8B5

P304

Q37859892-C2D5667B-FEB9-45E4-B939-CF1F8B0B6685

P31

Q37859892-474D1282-A0AE-4815-8B53-724EBA0BC052

P356

Q37859892-58F55B65-7EAB-4828-B7F0-8E250441D4DA

P407

Q37859892-BF8E87F0-9F83-4CC3-A4B2-54B87512FE8F

P433

Q37859892-FB8188B0-AAD9-4ACD-8E06-A0650022AFCE

P478

Q37859892-D34AF6F3-138F-41BD-B995-EC43BDC81A41

P577

Q37859892-6C2AAFE5-7183-44D6-921F-3206BBB42163

P698

Q37859892-4EF04DE3-A946-4C16-9225-AE24C3BFEC32

P932

Q37859892-CB6E5515-BB82-4321-B52F-5177B2C0ABA0

P356

P1433

Infection and Immunity

P1476

Reversal of the antichlamydial ...... secretion inhibitors by iron.

@en

P2093

Anatoly Slepenkin

http://www.w3.org/2001/XMLSchema#string

Ellena M Peterson

http://www.w3.org/2001/XMLSchema#string

Luis M de la Maza

http://www.w3.org/2001/XMLSchema#string

Mikael Elofsson

http://www.w3.org/2001/XMLSchema#string

Per-Anders Enquist

http://www.w3.org/2001/XMLSchema#string

Ulrik Hägglund

http://www.w3.org/2001/XMLSchema#string

P2860

Genome Sequence of an Obligate Intracellular Pathogen of Humans: Chlamydia trachomatis

A chlamydial type III translocated protein is tyrosine-phosphorylated at the site of entry and associated with recruitment of actin

Chlamydia trachomatis type III secretion: evidence for a functional apparatus during early-cycle development.

Targeting bacterial virulence: inhibitors of type III secretion in Yersinia.

Secretion of predicted Inc proteins of Chlamydia pneumoniae by a heterologous type III machinery.

Characterization of a neutralizing monoclonal antibody directed at the lipopolysaccharide of Chlamydia pneumoniae.

Small-molecule inhibitors specifically targeting type III secretion.

Iron metabolism in pathogenic bacteria.

Analysis of putative Chlamydia trachomatis chaperones Scc2 and Scc3 and their use in the identification of type III secretion substrates.

Temporal expression of type III secretion genes of Chlamydia pneumoniae.

P304

3478-3489

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/IAI.00023-07

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P577

2007-04-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17470544

http://www.w3.org/2001/XMLSchema#string

P932

1932962

http://www.w3.org/2001/XMLSchema#string